CA2425539A1 — Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2003-04-11 · 23y expired
What this patent protects
The invention relates to a crystalline monohydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)ox y]- 9,9-dimethyl-3-oxa-9-azoniatrycyclo[3.3.1.02,4]nonane bromide, to a method f or producing the same, and to the use thereof in the production of a…
USPTO Abstract
The invention relates to a crystalline monohydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)ox y]- 9,9-dimethyl-3-oxa-9-azoniatrycyclo[3.3.1.02,4]nonane bromide, to a method f or producing the same, and to the use thereof in the production of a medicament , especially for producing a medicament that has an anticholinergic effect.</S DOAB>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.